← Back to Search

Topical Gel

Safety and Efficacy of Pro-ocular™ 1% in Daily Scleral Lens Wearing Patients With Ocular Graft-versus-Host Disease

Phase 2 & 3
Waitlist Available
Research Sponsored by Glia, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 weeks, 12 weeks

Summary

This trial tests a special eye gel for patients with a specific eye condition who wear special contact lenses. The gel helps reduce eye discomfort and dryness, allowing them to wear their lenses comfortably for longer periods.

Eligible Conditions
  • Graft Versus Host Disease (GVHD) of the Eye

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 weeks, 12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 weeks, 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Modified Symptom Assessment in Dry Eye Questionnaire, Global Score for nighttime without scleral lenses.
Secondary study objectives
Change in Blurred or Cloudy Vision in Glia Ocular Surface Disease Symptoms Questionnaire.
Change in Central Corneal Staining
Other study objectives
Change in Conjunctival lissamine staining using NEI scoring.
Change in Conjunctival redness using Efron scale with 0.5 steps (with and without scleral lenses).
Change in Corneal fluorescein staining using modified NEI scoring.
+5 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Pro-ocular™ Topical Gel 1%Experimental Treatment1 Intervention
Group II: VehiclePlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

Glia, LLCLead Sponsor
4 Previous Clinical Trials
192 Total Patients Enrolled

Media Library

Pro-ocular™ Topical Gel 1% (Topical Gel) Clinical Trial Eligibility Overview. Trial Name: NCT04769648 — Phase 2 & 3
Graft Versus Host Disease of the Eye Research Study Groups: Vehicle, Pro-ocular™ Topical Gel 1%
Graft Versus Host Disease of the Eye Clinical Trial 2023: Pro-ocular™ Topical Gel 1% Highlights & Side Effects. Trial Name: NCT04769648 — Phase 2 & 3
Pro-ocular™ Topical Gel 1% (Topical Gel) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04769648 — Phase 2 & 3
~9 spots leftby Dec 2025